Return to Home

Akero Therapeutics, Inc.

AKRO

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
June 25, 2024

Days Left:
-20

calendar

Akero Therapeutics, Inc. Form












Securities Fraud News does not share your information with others. There is no cost or obligation for you to submit.

Allegations

The filed complaint alleges that defendants made false statements and/or concealed that: (i) approximately 20% of the patients enrolled in the SYMMETRY study, a trial that purportedly tested efruxifermin ("EFX") in patients with nonalcoholic steatohepatitis (“NASH”) -induced cirrhosis, had cryptogenic cirrhosis and did not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (iii) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (iv) Akero had introduced a confounding factor into the SYMMETRY study’s design, materially influencing the study’s potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not rule out potential causes of each patient’s cirrhosis other than NASH; and (vi) consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Akero Therapeutics purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Akero Therapeutics during the relevant time frame, you have until June 25, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Find More Cases

Ticker Symbol Company Name Join Deadline
UNH UnitedHealth Group Inc. July 15, 2024 Join
TDOC Teladoc Health, Inc. July 16, 2024 Join
CMBM Cambium Networks Corporation July 22, 2024 Join
BIIB Biogen Inc. July 22, 2024 Join
FSLY Fastly, Inc. July 23, 2024 Join
ENPH Enphase Energy, Inc. July 29, 2024 Join
RIVN Rivian Automotive, Inc. July 30, 2024 Join
HTZ Hertz Global Holdings, Inc. July 30, 2024 Join
HUM Humana Inc. August 02, 2024 Join
MRNS Marinus Pharmaceuticals, Inc. August 05, 2024 Join
SMG The Scotts Miracle-Gro Company August 05, 2024 Join
GRTS Gritstone bio, Inc. August 06, 2024 Join
RBLX Roblox Corporation August 12, 2024 Join
TWOU 2U, Inc. August 12, 2024 Join
LW Lamb Weston Holdings, Inc. August 12, 2024 Join
TDC Teradata Corporation August 13, 2024 Join
NKE NIKE, Inc. August 19, 2024 Join
PATH UiPath, Inc. August 19, 2024 Join
FF FutureFuel Corp. August 23, 2024 Join
TM Toyota Motor Corporation August 23, 2024 Join
SRG Seritage Growth Properties August 30, 2024 Join
MDB MongoDB, Inc. September 09, 2024 Join
WBA Walgreens Boots Alliance, Inc. September 10, 2024 Join